Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis-Reference-Cited by-同舟云学术

Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis

Published:2022-12-05 Issue:7 Volume:18 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Cai Qi¹,Huo Geng-wei¹,Zhu Fu-yi¹,Yue Ping¹,Yuan Dong-qi¹,Chen Peng¹

Affiliation:

1. Department of Thoracic Oncology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Lung Cancer Center, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

Funder

no funding

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2022.2145102

Reference50 articles.

1. The future of immune checkpoint therapy

2. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers

3. Immune checkpoint inhibitors: An innovation in immunotherapy for the treatment and management of patients with cancer